[A Case Report of Coexistence of EGFR and ROS-1 Gene Mutations 
in Non-small Cell Lung Cancer].

Lung cancer represents one of the most prevalent malignant tumors globally, and its treatment has entered the era of targeted therapy. The epidermal growth factor receptor (EGFR) mutation is a common type of genetic mutation in non-small cell lung cancer (NSCLC), while c-ros oncogene 1 receptor tyrosine kinase (ROS-1) fusion mutation is a rare mutation site. Currently, there are few case reports on the coexistence of EGFR and ROS-1 gene mutations. This study reports a case of NSCLC with coexisting EGFR and ROS-1 gene mutations, aiming to provide relevant treatment strategies for clinical practice. .

Authors

Institutions

Publication Details

Journal
PubMed
Published
2025-06-20
DOI
https://doi.org/10.3779/j.issn.1009-3419.2025.102.26
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

[A Case Report of Coexistence of EGFR and ROS-1 Gene Mutations 
in Non-small Cell Lung Cancer].

Yongshui Fu, Juan Zhao, Mingli Zhao, Jinming Yu et al.
PubMed
Lung Cancer Treatments and Mutations
article

[A Case Report of Coexistence of EGFR and ROS-1 Gene Mutations 
in Non-small Cell Lung Cancer].

Yongshui Fu, Juan Zhao, Mingli Zhao, Jinming Yu, Yan Zhao
article en

Abstract

Lung cancer represents one of the most prevalent malignant tumors globally, and its treatment has entered the era of targeted therapy. The epidermal growth factor receptor (EGFR) mutation is a common type of genetic mutation in non-small cell lung cancer (NSCLC), while c-ros oncogene 1 receptor tyrosine kinase (ROS-1) fusion mutation is a rare mutation site. Currently, there are few case reports on the coexistence of EGFR and ROS-1 gene mutations. This study reports a case of NSCLC with coexisting EGFR and ROS-1 gene mutations, aiming to provide relevant treatment strategies for clinical practice. .

PubMedVol. 28(6)
Kunming Medical University (CN)
Openalex Percentile: Top 73%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.